BioInsights - Technology innovation to address challenges in gene therapy manufacture

Technology innovation to address challenges in gene therapy manufacture

Cell and Gene Therapy Insights 2023; 9(1), 99;

DOI: 10.18609/cgti.2023.014

Published: 10 March 2023
Tania D Pereira Chilima

Watch the video or view the poster to learn more about:

The importance of technology selection on product quantity and quality

  • The role of cell immobilization in enabling continuous processing in LV manufacture
  • The effect of upstream technology in DSP costs, duration and complexity
  • Impact of process integration and automation in enabling continuous processing and reducing cost of goods

Tania D Pereira Chilima is the Chief Technology Officer at Univercells Technologies where she focuses on driving innovation to execute our mission of making biologics globally available and affordable. She also oversees the direction of the technology portfolio and is responsible for continuously identifying new technologies that could complement our portfolio as well as the application of our systems to new modalities. Prior to this role, she was Product Manager for the NevoLine™ platform at Univercells, and previously worked as a post-doctorate researcher for the ULTRA grant sponsored by the Bill and Melinda Gates foundation, focused on designing manufacturing strategies for ultra-low-cost vaccine manufacture. Tania holds an engineering doctorate from the University College London in partnership with Pall Life Sciences entitled “Decisional Tools for Enabling Successful Manufacture and Commercialization of Cell Therapy Products”, and is a frequent contributor to industry publications and journals